I am a board-certified hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center.
My clinical expertise is in treating patients with chronic myeloid leukemia (CML) as well as other myeloproliferative disorders, including myelofibrosis, polycythemia and thrombocytosis as well as less common conditions such as eosinophillic and mast cell disorders. My patient care philosophy is to offer in-depth explanation regarding diagnoses and to engage in active partnership with my patients and their referring providers to personalize decision-making and monitoring given the chronic nature of the disorders I treat.
Before joining Memorial Sloan Kettering, I was on the faculty of Oregon Health and Sciences University for 13 years. There I directed the CML clinical trial program and was involved in the early development and sentinel clinical study of targeted therapy for CML from imatinib (Gleevec) onwards. I completed both residency and fellowship training at the NewYork-Presbyterian Hospital / Weill Cornell Medical College in Manhattan.